Abstract | OBJECTIVES: METHODS: Twelve rabbit hearts were excised and retrogradely perfused employing the Langendorff setup. Left and right atrial catheters were used to record monophasic action potentials and to obtain cycle length-dependent atrial action potential durations (aAPD90) and effective refractory periods (aERP). After obtaining baseline data, 0.5 µmol/L levosimendan was infused. Subsequently, 10 µmol/L ranolazine was administered. RESULTS: Infusion of levosimendan led to a reduction of aAPD90 (-9 ms, p < 0.05) and aERP (-13 ms, p < 0.05). Additional treatment with ranolazine prolonged aAPD90 (+23 ms, p < 0.01) and aERP (+30 ms, p < 0.05). Under baseline conditions, a predefined pacing protocol induced 77 episodes of atrial fibrillation. Infusion of levosimendan enhanced the vulnerability to atrial fibrillation (132 episodes, p = 0.14). Further treatment with ranolazine had a significant antiarrhythmic effect (61 episodes, p < 0.05). CONCLUSIONS:
|
Authors | Christian Ellermann, Anja Kohnke, Dirk G Dechering, Simon Kochhäuser, Florian Reinke, Michael Fehr, Lars Eckardt, Gerrit Frommeyer |
Journal | Pharmacology
(Pharmacology)
Vol. 102
Issue 3-4
Pg. 138-141
( 2018)
ISSN: 1423-0313 [Electronic] Switzerland |
PMID | 29982246
(Publication Type: Journal Article)
|
Copyright | © 2018 S. Karger AG, Basel. |
Chemical References |
- Anti-Arrhythmia Agents
- Hydrazones
- Pyridazines
- Simendan
- Ranolazine
|
Topics |
- Action Potentials
(drug effects)
- Animals
- Anti-Arrhythmia Agents
(pharmacology)
- Atrial Fibrillation
(chemically induced, prevention & control)
- Drug Interactions
- Hydrazones
(antagonists & inhibitors, toxicity)
- Pyridazines
(antagonists & inhibitors, toxicity)
- Rabbits
- Ranolazine
(pharmacology)
- Refractory Period, Electrophysiological
(drug effects)
- Simendan
|